PTPN11 and head and neck squamous cell carcinoma: We next sought to understand which HNSCCs made up the sensitive group which could potentially enable biomarker-directed clinical trials in HNSCC and to also better understand the mechanism of SHP2 inhibitor efficacy in HNSCC.